[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genodermatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genodermatosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100526566","phase-2-a-44-week-monocentric-open-study-assessing-the-efficacy-and-safety-of-deucravacitinib-in-adults-with-inflammatory-genodermatoses-100526566",false,"NCT06136403","A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses","GENEPID","Inclusion Criteria:\n\n* Subject has congenital skin fragility with skin and\u002For mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS by KRT5 and\u002For 14 mutation (autosomal only) OR a clinical phenotype of inflammatory ichthyosis (IC) including keratinopathic ichthyosis due to KRT1\u002F10 mutation, ECI with identified genetic mutations (TGM5, NIPAL4, ABCA12, etc…).\n* Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS \\> 50\u002F128.\n\n  * Subject agrees not to use any topical therapies other than the investigator approved.\n\nExclusion Criteria:\n\n* Subjects with another form of ICI ie Netherton syndrome, Kid syndrome etc.\n* Infectious\u002FImmune-related Exclusions\n* Medical History and Concurrent Diseases","ALL","18 Years","99 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.\n\nParticipants will take treatments and have to use bullets during the study period.",[27,28,29,30],"Epidermolysis Bullosa Simplex","Ichthyosis","Genodermatosis","Inflammatory Congenital Ichthyoses",[32],"deucravacitinib","RECRUITING","2025-07-31",{"date":36,"type":37},"2025-08-05","ACTUAL",{"date":39,"type":37},"2024-03-18",{"date":41,"type":21},"2026-10-12",{"name":43,"class":44},"Centre Hospitalier Universitaire de Nice","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100555276","phase-2-a-20-week-study-assessing-the-efficacy-of-apremilast-in-patients-with-eb-simplex-generalized-100555276","NCT06509984","A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized","EBULO. a 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 Years of Age with EB Simplex Generalized","EBULO","Inclusion Criteria:\n\n* Male or female patients 6 years or older\n* Laboratory confirmed diagnosis of EBS-sev due to KRT5 or 14 mutation (autosomal)\n* Mean daily number of new blisters \\>3.\n* Subject\u002Fcaregiver agrees not to use any topical therapies other than the investigator approved\n\nExclusion Criteria:\n\n* \\- EBS lesions requiring oral therapy to treat an infection\n* Use of any diacerein containing product within 6 months prior to Visit 1\n* Use of systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Visit 1\n* Use of systemic steroidal therapy within 30 days prior to Visit 1\n* Use of any systemic product that, in the opinion of the investigator, might put the subject at undue risk by study participation or interferes with the study assessments within 30 days prior to Visit 1","6 Years",{"count":55,"type":21},20,[24],"The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \\> 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment.\n\nParticipants will take treatments and have to use bullets during the study period.",[27,29],[60,61,62],"Apremilast","Children","Pediatric","2025-02-21",{"date":65,"type":37},"2025-02-24",{"date":67,"type":37},"2024-08-06",{"date":69,"type":21},"2026-04-01",{"name":43,"class":44},4]